Medical/Pharmaceuticals
AACR OVARIAN CANCER CONFERENCE PRESENTATION
HIGHLIGHTS * Data from preclinical studies in ovarian cancer presented at premier international conference inBoston, USA. * Results indicate that Amplia's proprietary FAK inhibitor narmafotinib (AMP945) performs better than standard-of-care in models of chemotherapy-resistant high-grade ser...
2023-10-09 15:18
2293
CANbridge Announces Marketing Approval of CAN108 (/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)
* LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS * LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally BEIJING and BURLINGTON, Mass. ,Oct. 8, 2023 /PRNewswire/ -- CANbridge Pha...
2023-10-09 08:00
2573
FDA Grants Orphan Drug Designation to GC Biopharma's Drug Candidate for Thrombotic Thrombocytopenic Purpura
YONGIN, South Korea, Oct. 5, 2023 /PRNewswire/ -- GC Biopharma Corp. announced today that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura (TTP), received an Orphan Drug Designation onSeptember 27 from the U.S. Food and Drug Administration (FDA). When designated as an orphan...
2023-10-06 08:12
3260
STARmed America Launches, Pioneering Thermal Ablation Innovations in North America
LOS ANGELES, Oct. 5, 2023 /PRNewswire/ -- STARmed Co., Ltd
2023-10-05 20:00
3075
LOTTE BIOLOGICS Announces Land Purchase Agreement with Incheon Free Economic Zone Authority, Establishing New Foothold in Songdo
* Construction of a Bio Plant with a total production capacity of 360 kL at Songdo's Block KI20, Zone 11 by 2030 * Aims to secure capabilities of an international standard and expand client base by making the Bio Plant a key hub SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- LOTTE BIOLOGICS...
2023-10-04 18:14
2757
First patient treated with Cu-67 SAR-Bombesin in theranostic prostate cancer trial
SYDNEY, Oct. 3, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the dosing of the first ...
2023-10-03 20:58
2887
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
- CBL-0202 Phase 2 study results met all the primary and secondary endpoints. - 69.9% and 60.9% of participants lost at least 150mL and 200mL of abdominal subcutaneous fat in the treated area after CBL-514 treatment. - Compared with placebo, an average of 312.1mL of subcutaneous fat was reduced in...
2023-10-02 21:00
2183
Flat Medical Secures Series C Funding Led by Taiwania Capital, Poised for Global Market Expansion
TAIPEI, Oct. 2, 2023 /PRNewswire/ -- Flat Medical, the leading medtech company specializing in innovative safety solutions for anesthesia, pain medicine, critical care and emergency medicine, is thrilled to announce the successful closing of its Series C funding round. The round was led by renown...
2023-10-02 20:30
2701
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
WUXI, China, Oct. 1, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics ("Amicus") (Nasdaq: FOLD), on receiving U.S. FDA's approval for Pombili...
2023-10-02 08:30
2293
Akeso and RemeGen Collaborate on Clinical Study Exploring the Potential of PD-1/CTLA-4 Bispecific Antibody with HER-2 ADC Combination Therapy in Gastric Cancer
HONG KONG, Sept. 29, 2023 /PRNewswire/ -- On September 28, 2023, Akeso (9926.HK) announced that its subsidiary, Akeso Pharma, will collaborate with RemeGen (Yantai) Co., Ltd. (688331.SH/09995.HK) to advance the development of Akeso's globally first PD-1/CTLA-4 bispecific antibody, cadonilimab ...
2023-09-29 20:00
3842
Jin Medical International Limited Receives NASDAQ Notification Letter Regarding Noncompliance with Continued Listing Rule 5550(a)(3)
CHANGZHOU, China, Sept. 28, 2023 /PRNewswire/ -- Jin Medical International Ltd. ("JinMed" or "the Company") (NASDAQ: ZJYL), aCayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, received a written notification letter ("t...
2023-09-29 04:30
2799
AMRIC, A New Premium Imaging Clinic on Manhattan's Upper East Side Featuring Cutting-Edge Scanners from United Imaging, Opens its Doors
Focusing on every detail, the clinic combines advanced multi-modality technology with highly tailored patient care to bring a new standard of preventive and diagnostic screenings to the center ofNew York City. HOUSTON, Sept. 28, 2023 /PRNewswire/ -- United Imaging, a leading global manufacturer...
2023-09-29 00:00
3189
SGC and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
CHENGDU, China, Sept. 28, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced that it has entered into a partnership with The Structural Genomics Consortium ("SGC"), a public-private partnership that supports the discovery of new medi...
2023-09-28 21:30
2690
ProfoundBio Announces Upcoming Scientific Presentations at SITC 2023
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate (ADC) therapeutics for cancer, announced four upcoming poster presentations on its ADC platform and lead clinical assets, rinatabart sesutecan (...
2023-09-28 20:00
3132
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
SHANGHAI, Sept. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH) , an innovative biopharmaceutical company with entire industry chain, announced the first patient was dosed in a phase Ib/II trial of its novel Nectin-4 targeting ADC (R&D code: 9MW2821) in combination with PD-1 inhibitor for the treatm...
2023-09-28 20:00
1978
IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023
82.4% of patients without prior CAR-T achieving Complete Response (CR) or better SHANGHAI and NANJING, China and SAN JOSE, Calif., Sept. 28, 2023 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and ant...
2023-09-28 18:09
2154
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
HONG KONG, Sept. 27, 2023 /PRNewswire/ -- Akeso, Inc. (the Company, Akeso, 9926.HK) announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for AK117, a next generation CD47 monoclonal antibody in combination with azaciti...
2023-09-28 10:07
2647
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China
WUXI, China, Sept. 27, 2023 /PRNewswire/ -- September 25th, 2023, BioCity Biopharma and AstraZeneca signed an agreement to collaborate on a Phase Ib/II clinical study to evaluate the safety and efficacy of BioCity's BC3402, a monoclonal antibody (mAb) targeting the T cell immunoglobulin and muci...
2023-09-28 09:46
2585
Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting
- Lunit's 6 posters unveil new tumor microenvironment insights and the predictive power of Lunit SCOPE across diverse cancer types at SITC 2023 SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeu...
2023-09-27 22:03
2934
Emotional Link LLC CEO Naoto Sato Interviews Associate Professor Mai Uchida, Harvard Medical School, on "How to deal with Blowing up on SNS"
TOKYO, Sept. 27, 2023 /PRNewswire/ -- Emotional Link LLC
2023-09-27 22:00
3544
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 292 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8684
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7954
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
7116
